Trial Profile
A phase I/II study of VM200 for the treatment of Stargardt disease
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 17 Nov 2015
Price :
$35
*
At a glance
- Drugs VM 200 (Primary)
- Indications Stargardt disease
- Focus Adverse reactions; Therapeutic Use
- 17 Nov 2015 New trial record
- 09 Nov 2015 According to a company media release, Vision Medicines plans to initiate this study in 2016.